{
  "id": 12745595,
  "title": "Recursion Pharmaceuticals director Blake Borgeson sells $242,000 in stock",
  "url": "https://urgent.news/2026/10/08/recursion-pharmaceuticals-director-blake-borgeson-sells-242-000-in",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-08T00:16:01.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/recursion-pharmaceuticals-director-blake-borgeson-sells-242000-in-stock-93CH-4937752"
  },
  "original_language": "en",
  "account": "Director Blake Borgeson of Recursion Pharmaceuticals sold a total of $242,000 worth of the company's Class A Common Stock on October 6, 2026. This transaction involved the sale of 50,000 shares at an average price of $4.84 per share. The sales were made in several trades, with individual prices between $4.80 and $5.00. The stock sale was executed under a Rule 10b5-1 trading plan established by Mr. Borgeson on August 31, 2025. Following the sale, Mr. Borgeson retains ownership of 6,108,287 shares of Recursion Pharmaceuticals. Since the transaction, the stock has experienced volatility, currently trading at $4.27, which is below the price at which Mr. Borgeson sold his shares. According to InvestingPro, the stock appears undervalued at current levels based on fair value metrics. Over the past six months, Recursion Pharmaceuticals has achieved a 26% return. InvestingPro identifies 10 additional key insights for RXRX investors and provides a comprehensive Pro Research Report for this and 1,400+ other US equities. Recently, Recursion Pharmaceuticals reported weaker-than-expected financial results for the second quarter of 2026, with a wider-than-anticipated loss and revenue falling short of expectations. The company has adjusted its full-year cash operating expense guidance to $375 million. Despite these setbacks, Recursion Pharmaceuticals holds a cash balance of approximately $557 million, which is anticipated to sustain operations until early 2028.",
  "summary": null,
  "key_points": [
    "Recursion Pharmaceuticals director Blake Borgeson sold $242,000 worth of stock on October 6, 2026.",
    "The sale involved 50,000 shares at an average price of $4.84 per share.",
    "Borgeson retains 6,108,287 shares; Recursion's stock traded below $4.84 post-sale."
  ],
  "editors_take": "The sale of Recursion Pharmaceuticals stock by director Blake Borgeson under a pre-established trading plan does not necessarily indicate a loss of confidence in the company, but rather a routine financial management move.",
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Director Hershberg sells $125k in Recursion Pharmaceuticals stock",
        "url": "https://urgent.news/2026/10/08/director-hershberg-sells-125k-in-recursion-pharmaceuticals-stock",
        "published": "2026-10-08T00:01:40.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}